Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL versus BONSITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL versus BONSITY.
ACTONEL vs BONSITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Selective estrogen receptor modulator (SERM); binds to estrogen receptors, exerting agonistic effects on bone and lipid metabolism and antagonistic effects on breast and uterine tissue.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
10 mg orally once daily, taken with or without food.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Terminal elimination half-life is approximately 24-30 hours; this supports once-daily dosing. Half-life may be prolonged in renal impairment.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Renal excretion of unchanged drug accounts for 60-70% of the administered dose; biliary/fecal elimination comprises 20-25% as metabolites and unchanged drug.
Category C
Category C
Bisphosphonate
Bisphosphonate